Plasma Agouti-Related Protein and Cortisol Levels in Cushing Disease: Evidence for the Regulation of Agouti-Related Protein by Glucocorticoids in Humans
Open Access
- 28 December 2018
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (3) , 961-969
Abstract
Context Glucocorticoids regulate energy balance, in part by stimulating the orexigenic neuropeptide agouti-related protein (AgRP). AgRP neurons express glucocorticoid receptors, and glucocorticoids have been shown to stimulate AgRP gene expression in rodents. Objective We sought to determine whether there is a relationship between plasma AgRP and hypothalamic AgRP in rats and to evaluate the relationship between cortisol and plasma AgRP in humans. Methods We retrospectively evaluated plasma AgRP levels prior to transsphenoidal surgery in 31 patients with Cushing disease (CD) vs 31 sex- and body mass index–matched controls from a separate study. We then prospectively measured plasma AgRP, before and 6 to 12 months after surgery, in a subgroup of 13 patients with CD. Plasma and hypothalamic AgRP were measured in adrenalectomized rats with and without corticosterone replacement. Results Plasma AgRP was stimulated by corticosterone in rats and correlated with hypothalamic AgRP expression. Plasma AgRP levels were higher in patients with CD than in controls (139 ± 12.3 vs 54.2 ± 3.1 pg/mL; P < 0.0001). Among patients with CD, mean 24-hour urine free cortisol (UFC) levels were 257 ± 39 μg/24 hours. Strong positive correlations were observed between plasma AgRP and UFC (r = 0.76; P < 0.0001). In 11 of 13 patients demonstrating surgical cure, AgRP decreased from 126 ± 20.6 to 62.5 ± 8.0 pg/mL (P < 0.05) postoperatively, in parallel with a decline in UFC. Conclusions Plasma AgRP levels are elevated in CD, are tightly correlated with cortisol concentrations, and decline with surgical cure. These data support the regulation of AgRP by glucocorticoids in humans. AgRP’s role as a potential biomarker and as a mediator of the adverse metabolic consequences of CD deserves further study.Keywords
Funding Information
- Robert Wood Johnson Foundation (71591)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK093920)
- National Center for Advancing Translational Sciences (UL1 TR000040)
This publication has 35 references indexed in Scilit:
- Unraveling the Central Proopiomelanocortin Neural CircuitsFrontiers in Neuroscience, 2013
- Central nervous control of energy and glucose balance: focus on the central melanocortin systemAnnals of the New York Academy of Sciences, 2011
- Glucocorticoids increase NPY gene expression in the arcuate nucleus by inhibiting mTOR signaling in rat hypothalamic organotypic culturesPeptides, 2010
- Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing’s syndromeEuropean Journal of Endocrinology, 2007
- The central melanocortin system and the regulation of energy balanceFrontiers in Bioscience-Landmark, 2007
- The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH‐dependent Cushing's syndromeClinical Endocrinology, 2006
- Central nervous system control of food intake and body weightNature, 2006
- Insulin Inhibits Neuropeptide Y Gene Expression in the Arcuate Nucleus through GABAergic SystemsJournal of Neuroscience, 2005
- Effects of fasting, leptin, and insulin on AGRP and POMC peptide release in the hypothalamusBrain Research, 2005
- Petrosal Sinus Sampling with and without Corticotropin-Releasing Hormone for the Differential Diagnosis of Cushing's SyndromeNew England Journal of Medicine, 1991